• Something wrong with this record ?

Cryopreservation of apheresis platelets treated with riboflavin and UV light

D. Kutac, M. Bohonek, L. Landova, E. Staskova, M. Blahutova, I. Malikova, M. Slouf, JM. Horacek, LG. Stansbury, JR. Hess, J. Seghatchian

. 2023 ; 62 (2) : 103580. [pub] 20220919

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23003721

BACKGROUND: Pathogen reduction technology (PRT) is increasingly used in the preparation of platelets for therapeutic transfusion. As the Czech Republic considers PRT, we asked what effects PRT may have on the recovery and function of platelets after cryopreservation (CP), which we use in both military and civilian blood settings. STUDY DESIGN AND METHODS: 16 Group O apheresis platelets units were treated with PRT (Mirasol, Terumo BCT, USA) before freezing; 15 similarly collected units were frozen without PRT as controls. All units were processed with 5-6% DMSO, frozen at - 80 °C, stored > 14 days, and reconstituted in thawed AB plasma. After reconstitution, all units were assessed for: platelet count, mean platelet volume (MPV), platelet recovery, thromboelastography, thrombin generation time, endogenous thrombin potential (ETP), glucose, lactate, pH, pO2, pCO2, HCO3, CD41, CD42b, CD62, Annexin V, CCL5, CD62P, and aggregates > 2 mm and selected units for Kunicki score. RESULTS: PRT treated platelet units had lower platelet number (247 vs 278 ×109/U), reduced thromboelastographic MA (38 vs 62 mm) and demonstrated aggregates compared to untreated platelets. Plasma coagulation functions were largely unchanged. CONCLUSIONS: Samples from PRT units showed reduced platelet number, reduced function greater than the reduced number would cause, and aggregates. While the platelet numbers are sufficient to meet the European standard, marked platelets activation with weak clot strength suggest reduced effectiveness.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003721
003      
CZ-PrNML
005      
20231221120136.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.transci.2022.103580 $2 doi
035    __
$a (PubMed)36167613
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kutac, Dominik $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Czech Republic; Department of Military Internal Medicine and Military Hygiene, Faculty of Military Health Sciences, University of Defence in Brno, Hradec Kralove, Czech Republic. Electronic address: dominik.kutac@uvn.cz
245    10
$a Cryopreservation of apheresis platelets treated with riboflavin and UV light / $c D. Kutac, M. Bohonek, L. Landova, E. Staskova, M. Blahutova, I. Malikova, M. Slouf, JM. Horacek, LG. Stansbury, JR. Hess, J. Seghatchian
520    9_
$a BACKGROUND: Pathogen reduction technology (PRT) is increasingly used in the preparation of platelets for therapeutic transfusion. As the Czech Republic considers PRT, we asked what effects PRT may have on the recovery and function of platelets after cryopreservation (CP), which we use in both military and civilian blood settings. STUDY DESIGN AND METHODS: 16 Group O apheresis platelets units were treated with PRT (Mirasol, Terumo BCT, USA) before freezing; 15 similarly collected units were frozen without PRT as controls. All units were processed with 5-6% DMSO, frozen at - 80 °C, stored > 14 days, and reconstituted in thawed AB plasma. After reconstitution, all units were assessed for: platelet count, mean platelet volume (MPV), platelet recovery, thromboelastography, thrombin generation time, endogenous thrombin potential (ETP), glucose, lactate, pH, pO2, pCO2, HCO3, CD41, CD42b, CD62, Annexin V, CCL5, CD62P, and aggregates > 2 mm and selected units for Kunicki score. RESULTS: PRT treated platelet units had lower platelet number (247 vs 278 ×109/U), reduced thromboelastographic MA (38 vs 62 mm) and demonstrated aggregates compared to untreated platelets. Plasma coagulation functions were largely unchanged. CONCLUSIONS: Samples from PRT units showed reduced platelet number, reduced function greater than the reduced number would cause, and aggregates. While the platelet numbers are sufficient to meet the European standard, marked platelets activation with weak clot strength suggest reduced effectiveness.
650    _2
$a lidé $7 D006801
650    12
$a ultrafialové záření $7 D014466
650    _2
$a trombin $7 D013917
650    _2
$a konzervace krve $7 D001793
650    _2
$a trombocyty $x fyziologie $7 D001792
650    _2
$a riboflavin $x farmakologie $7 D012256
650    12
$a separace krevních složek $7 D001781
650    _2
$a kyselina mléčná $7 D019344
650    _2
$a kryoprezervace $7 D015925
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bohonek, Milos $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Czech Republic; Faculty of Biomedical Engineering, Czech Technical University in Prague, Czech Republic
700    1_
$a Landova, Ludmila $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Czech Republic
700    1_
$a Staskova, Eva $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Czech Republic
700    1_
$a Blahutova, Marie $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Czech Republic
700    1_
$a Malikova, Ivana $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty of Medicine, Charles University of Prague and the General University Hospital in Prague, Czech Republic
700    1_
$a Slouf, Miroslav $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Czech Republic
700    1_
$a Horacek, Jan M $u Department of Internal Medicine IV - Hematology, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Stansbury, Lynn G $u Harborview Injury Prevention Research Center, Harborview Medical Center, Seattle, WA, USA; Department of Anesthesia and Pain Medicine, University of Washington, Seattle, WA, USA
700    1_
$a Hess, John R. $u Harborview Injury Prevention Research Center, Harborview Medical Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA $7 xx0311953
700    1_
$a Seghatchian, Jerard $u International Consultancy in Blood Components Quality/Safety, Audit/Inspection and DDR Strategy, London, UK
773    0_
$w MED00008583 $t Transfusion and apheresis science $x 1473-0502 $g Roč. 62, č. 2 (2023), s. 103580
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36167613 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20231221120130 $b ABA008
999    __
$a ok $b bmc $g 1924411 $s 1189930
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 62 $c 2 $d 103580 $e 20220919 $i 1473-0502 $m Transfusion and apheresis science $n Transfus Apher Sci $x MED00008583
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options